Gene writers - Tessera Therapeutics
Latest Information Update: 26 Jun 2024
At a glance
- Originator Tessera Therapeutics
- Class Antianaemics; Antineoplastics; CAR-T cell therapies; Gene therapies; Haematopoietic stem cells therapies; Immunotherapies
- Mechanism of Action Cell replacements; Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alpha 1-antitrypsin deficiency; Cancer; Hepatolenticular degeneration; Phenylketonuria; Sickle cell anaemia
Most Recent Events
- 20 Jun 2024 Pharmacodynamics data from a preclinical studies in Alpha-1 antitrypsin deficiency released by Tessera therapeutics
- 10 May 2024 Preclinical trials in Alpha 1-antitrypsin deficiency in USA (Parenteral) prior to May 2024
- 10 May 2024 Preclinical trials in Cancer in USA (Parenteral) prior to May 2024